adagrasib
mirati
['nsclc', 'lung', 'sclc', 'adagrasib']
the kras g12c inhibitor adagrasib demonstrated an objective response rate of 43% and disease control rate of 80% among patients with previously treated kras g12c mutated non small cell lung cancer. #nsclc #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.